Spinnaker Investment Group LLC decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 6.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,360 shares of the company’s stock after selling 609 shares during the quarter. Spinnaker Investment Group LLC’s holdings in Johnson & Johnson were worth $1,209,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also bought and sold shares of the company. Summit Wealth Partners LLC increased its position in shares of Johnson & Johnson by 0.6% in the 2nd quarter. Summit Wealth Partners LLC now owns 10,007 shares of the company’s stock valued at $1,463,000 after purchasing an additional 61 shares during the last quarter. Powers Advisory Group LLC increased its holdings in Johnson & Johnson by 0.6% in the third quarter. Powers Advisory Group LLC now owns 9,489 shares of the company’s stock valued at $1,538,000 after buying an additional 61 shares during the last quarter. Eagle Wealth Strategies LLC raised its stake in Johnson & Johnson by 2.8% in the third quarter. Eagle Wealth Strategies LLC now owns 2,294 shares of the company’s stock valued at $372,000 after buying an additional 63 shares in the last quarter. Knuff & Co LLC boosted its position in shares of Johnson & Johnson by 0.7% during the 3rd quarter. Knuff & Co LLC now owns 9,466 shares of the company’s stock worth $1,534,000 after acquiring an additional 64 shares in the last quarter. Finally, Perkins Coie Trust Co increased its holdings in shares of Johnson & Johnson by 1.8% in the 3rd quarter. Perkins Coie Trust Co now owns 3,705 shares of the company’s stock valued at $600,000 after acquiring an additional 65 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.
Johnson & Johnson Price Performance
Shares of NYSE:JNJ opened at $146.76 on Monday. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $168.85. The company has a 50-day moving average price of $147.85 and a 200 day moving average price of $156.06. The company has a market cap of $353.34 billion, a P/E ratio of 22.07, a PEG ratio of 2.45 and a beta of 0.51. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45.
Johnson & Johnson Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be issued a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.38%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is currently 74.59%.
Analyst Ratings Changes
Several equities analysts have commented on JNJ shares. Citigroup dropped their price target on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research note on Wednesday, December 11th. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Guggenheim upped their price objective on shares of Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a research note on Wednesday, November 6th. Bank of America reduced their target price on Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating for the company in a report on Thursday. Finally, Wolfe Research initiated coverage on Johnson & Johnson in a research report on Friday, November 15th. They set an “outperform” rating and a $190.00 price target on the stock. Nine investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $170.06.
View Our Latest Stock Analysis on Johnson & Johnson
Insiders Place Their Bets
In other news, Director Mark A. Weinberger purchased 1,000 shares of the stock in a transaction that occurred on Thursday, December 12th. The shares were acquired at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the acquisition, the director now directly owns 1,000 shares in the company, valued at approximately $147,220. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.16% of the stock is currently owned by company insiders.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Featured Stories
- Five stocks we like better than Johnson & Johnson
- With Risk Tolerance, One Size Does Not Fit All
- MP Materials: Rare Earth Elements Powering the EV Boom
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Verizon’s Turnaround Gains Traction: New Highs Are Likely in 2025
- Investing in Commodities: What Are They? How to Invest in Them
- Bloom Energy: Powering the Future With Decentralized Energy
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.